Holen Sie sich die Stockscreener-App
276.12
1.92%
-5.3087
Schlusskurs vom Vortag:
$281.43
Offen:
$281.43
24-Stunden-Volumen:
984.86K
Relative Volume:
0.70
Marktkapitalisierung:
$46.43B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$780.66M
KGV:
58.50
EPS:
4.72
Netto-Cashflow:
$1.20B
1W Leistung:
-2.31%
1M Leistung:
+14.64%
6M Leistung:
+23.15%
1J Leistung:
+50.18%
1-Tages-Spanne:
$274.93
$284.02
1-Wochen-Bereich:
$274.93
$285.06
52-Wochen-Spanne:
$177.41
$291.69
Veeva Systems Inc Stock (VEEV) Company Profile
Firmenname
Veeva Systems Inc
Sektor
Branche
Telefon
925-452-6500
Adresse
4280 HACIENDA DRIVE, PLEASANTON, CA
Vergleichen Sie VEEV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
276.12 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
67.94 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
57.13 | 10.79B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
100.87 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.83 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-29 | Bestätigt | Needham | Buy |
| 2025-01-23 | Herabstufung | Goldman | Buy → Sell |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-12-04 | Eingeleitet | Mizuho | Outperform |
| 2024-11-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-08 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2024-08-27 | Bestätigt | Citigroup | Buy |
| 2024-07-09 | Eingeleitet | BTIG Research | Buy |
| 2023-10-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-28 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Truist | Buy → Hold |
| 2023-02-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-04 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-06 | Eingeleitet | Cowen | Market Perform |
| 2022-12-02 | Bestätigt | Needham | Buy |
| 2022-10-31 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | Goldman | Buy |
| 2022-06-21 | Fortgesetzt | Guggenheim | Buy |
| 2022-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2022-01-07 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Fortgesetzt | Stifel | Buy |
| 2021-09-02 | Bestätigt | BofA Securities | Buy |
| 2021-09-02 | Bestätigt | JMP Securities | Mkt Outperform |
| 2021-09-02 | Bestätigt | Needham | Buy |
| 2021-09-02 | Bestätigt | UBS | Neutral |
| 2021-07-21 | Eingeleitet | Cowen | Outperform |
| 2021-03-31 | Hochstufung | UBS | Sell → Neutral |
| 2021-01-07 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-10-14 | Fortgesetzt | UBS | Sell |
| 2020-08-28 | Bestätigt | Needham | Buy |
| 2020-07-23 | Eingeleitet | FBN Securities | Outperform |
| 2020-07-07 | Eingeleitet | Stephens | Overweight |
| 2020-06-08 | Eingeleitet | Citigroup | Buy |
| 2020-05-29 | Bestätigt | Needham | Buy |
| 2020-04-13 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-14 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | Bestätigt | Canaccord Genuity | Hold |
| 2019-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | Bestätigt | Needham | Buy |
| 2019-06-07 | Eingeleitet | Goldman | Neutral |
| 2019-05-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-27 | Bestätigt | Needham | Buy |
Alle ansehen
Veeva Systems Inc Aktie (VEEV) Neueste Nachrichten
Alcon and Merit Medical: Creating Regulatory and Quality Business Value with AI - Veeva
How to Use the Zacks Rank to Find Top Stocks - TradingView
Veeva Systems: The Strong Quarter May Be A First Of Many To Come (VEEV) - Seeking Alpha
Cook Medical: Empowering Change Champions for a Global RIM Rollout - Veeva
VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma - Yahoo Finance
Veeva Systems and PulteGroup have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Bull of the Day: Veeva Systems (VEEV) - Zacks Investment Research
Veeva Systems’ SWOT analysis: cloud leader faces competition in life sciences stock - Investing.com Nigeria
Radiometer Scales Clinical Trials with Unified Clinical Platform - Veeva
Veeva Systems Inc. (VEEV) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Why Veeva Systems (VEEV) is a Top Momentum Stock for the Long-Term - Yahoo Finance
New Veeva China Campaign Manager Drives Precision Omnichannel Marketing for Life Sciences - Veeva
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility - The Motley Fool
Veeva Systems (NYSE:VEEV) Powers Medtech Trials with Expanded Clinical Platform Adoption - Yahoo Finance
DOCS Boosts Client Retention via Workflow Integration and AI Tools - TradingView
Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech - MarketScreener
Medtech Industry Establishes Foundation for Clinical Trials with - GuruFocus
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech – Company Announcement - Financial Times
Should You Expect a Large Market Opportunity for Veeva Systems (VEEV)? - MSN
Veeva Systems Inc. (VEEV): A Bull Case Theory - MSN
New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years - Veeva
Veeva Systems director Timothy Cabral sells $841,734 in stock By Investing.com - Investing.com Nigeria
Jefferies Hikes Veeva Systems (VEEV) Price Target to $335, Maintains Buy Rating - MSN
The Rich Compensation for Being the C.E.O. - The New York Times
Veeva Systems Inc. (NYSE:VEEV) Short Interest Update - Defense World
Alcon: Achieving UDI Compliance with Veeva RIM - Veeva
Do Options Traders Know Something About Veeva Systems Stock We Don't? - Nasdaq
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know - MSN
Veeva Systems: AI And Vault CRM Are Key Long-Term Tailwinds (NYSE:VEEV) - Seeking Alpha
Astellas Chooses Veeva Vault CRM as Global Standard - Yahoo Finance
Transcript : Veeva Systems Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-04-2025 01 - marketscreener.com
Veeva Systems (NYSE:VEEV) Partners With Accumulus Synergy For Global Regulatory Connectivity - Yahoo
Veeva Systems stock soars to 52-week high of $286.99 By Investing.com - Investing.com Nigeria
Veeva Systems stock soars to 52-week high of $286.99 - Investing.com Australia
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials - BioSpace
Veeva Systems Signs Oncology Trial Software Deal With Sarah Cannon Research Institute - marketscreener.com
VEEV Teams Up with SCRI to Enhance Oncology Clinical Trials | VEEV Stock News - GuruFocus
Astellas Chooses Veeva Vault CRM as Global Standard | VEEV Stock News - GuruFocus
Astellas selects Veeva Vault CRM for global operations By Investing.com - Investing.com Canada
SCRI adopts Veeva platform for streamlined clinical trials By Investing.com - Investing.com Canada
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials | VEEV Stock News - GuruFocus
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation and Connectivity - marketscreener.com
Astellas Chooses Veeva Vault CRM as Global Standard – Company Announcement - Financial Times
Veeva Sees Inflows after Earnings Beat - FXEmpire
Decoding Veeva Systems Inc (VEEV): A Strategic SWOT Insight - GuruFocus
Transcript : Veeva Systems Inc. Presents at Baird Global Consumer, Technology & Services Conference 2025, Jun-03-2025 10 - marketscreener.com
Understanding Veeva (VEEV) Reliance on International Revenue - Yahoo Finance
Veeva Systems (NYSE:VEEV) Price Target Raised to $295.00 at Mizuho - Defense World
Finanzdaten der Veeva Systems Inc-Aktie (VEEV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.54%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):